Here, we identified that ENDX is a potent inhibitor of PKCβ1 kinase activity and moreover, ENDX may promote PKCβ1 protein degradation, opening up the exciting possibility for the potential development of PKCβ1-targeting ENDX PROTACs for ERα+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.